Cuba tests a vaccine against solid tumors

Cuban researchers at the Center for Genetic Engineering and Biotechnology (CIGB) in Havana test their own solid tumor vaccine, the "top priority" of the state-run Biocubafarma group, which also lists seven other drugs " high impact ". "Savax" is the trade name of the drug, which is in the second phase of testing to test its effectiveness on ovarian and hepatic tumors, the official journal Juventud Rebelde reported.

To reach this stage, the effect of Gerardo Guillén, director of biomedical research at CIGB,

"Nearly five years later, not only the increase in the expectation of lives of these patients, some of whom still live, but the total reduction of tumors in four of them, "Guillén said.

Despite success In the study phase, for the full application of the vaccine, "there are still many parameters that should be evaluated" by specialists and regulatory authorities, has -He specifies.

Next to the "Savax", the CIGB "works in priority". the year in new formulations of Heberprot-P, an effective treatment for treating diabetic foot ulcers and flagship project of Cuban biotechnology, registered in more than 20 countries, reports Informe 21.

They also list a synthetic peptide for the treatment of cardiac ischemia, a drug for rheumatoid arthritis and a treatment for cerebral ischemia.

The CIMAVAX-EGF vaccine against lung cancer stands out in the history of Havana's Engineering and Biotechnology Center, which also produces "Heberferon" "for the treatment of cancer of the lungs. skin and vaccines against hepatitis B and meningitis.

The CIGB subsidiary in Camagüey province (center) has also successfully produced Gavac, a vaccine for own production against cattle ticks. [19659002] The products of biotechnology and the pharmaceutical industry are among the leading export items of Cuba.